Diagnostic and Interventional Cardiology DAIC

Diagnostic and Interventional Cardiology (DAIC) is a magazine that reaches more than 25,000 healthcare professionals in cardiology, interventional cardiology and cath labs across the United States. These influential buying team members rely on DAIC's award-winning editorial content and comparison charts as a unique research tool for specifying, recommending and approving technology/device purchases.

News | Cardiovascular Business

Medicare Increases Hospital Outpatient Payment for Peripheral Intravascular Lithotripsy

November 10, 2021 — Shockwave Medical, a developer of Intravascular Lithotripsy (IVL) to treat complex calcified ...

November 10, 2021

News | Heart Failure

Ancora Heart AccuCinch System Shows Positive 12 Month Outcomes in Multi-study Analysis

November 10, 2021 — Ancora Heart Inc., a company developing a novel therapy to address heart failure, announced results ...

November 10, 2021

TCT 2021 Announces Late-Breaking Clinical Trials

Feature | TCT

Links to all the TCT 2021 Late-Breaking Clinical Trials

November 10, 2021 — There were nine late-breaking trials and 13 late-breaking science presentations at the 2021 Transcat ...

November 10, 2021

The Teleflex Manta large bore vascular closure device #TCT2021

News | Vascular Closure Devices

Plug-based Vascular Closure Following TAVR Offers Shorter Hemostasis Time Than Suture-based Devices

November 9, 2021 — Results from the largest randomized trial available comparing different closure device strategies ...

November 09, 2021

An illustration of the Recor renal denervation ablation balloon at work in the renal artery.. Renal Denervation Recor RDN ablation balloon #TCT2021

News | Hypertension

Renal Denervation Combined With Medication Can Treat Resistant Hypertension

November 9, 2021 — Six-month outcomes from the randomized RADIANCE-HTN TRIO Trial comparing endovascular ultrasound ...

November 09, 2021

TAVR CT image reconstruction of an implanted Medtronic CoreValve. #TCT21 #TCT #TAVR #SURTAVI

News | Heart Valve Technology

Intermediate-risk Patients Have Similar Five-year Outcomes With Transcatheter or Surgical Aortic Valve Replacement

November 9, 2021 — New five-year data from the SURTAVI trial found that there was no difference in all-cause mortality ...

November 09, 2021

A PARTNER 3 trial economic analysis shows for low surgical risk patients, TAVR is cost-saving compared with SAVR. TAVR Sapien Valve visualized using a GE guidance software. #TCT2021

News | Structural Heart

TAVR Is Cost Effective Compared With Surgical Replacement for Low-risk Patients

November 9, 2021 — An economic analysis of data from PARTNER 3, a randomized trial comparing transcatheter aortic valve ...

November 09, 2021

The two FDA-cleared transcatheter LAA occlusion devices on the U.S. market were compared in the SWISS-APERO and SEAL FLX trials presented at TCT 2021. Left is the Abbott Amulet device, right is the newest generation Watchman FLX device.

News | Left Atrial Appendage (LAA) Occluders

First Comparison of Amulet and Watchman FLX LAA Closure Devices Found Similar Outcomes

November 8, 2021 – SWISS-APERO is the first randomized clinical trial comparing the Abbott Amulet left atrial appendage ...

November 08, 2021

The Edwards Lifesciences Evoque transcatheter tricuspid valve replacement system demonstrated sustained favorable patient outcomes at six months in the TRISCEND study.

News | Structural Heart

Six-Month Outcomes Positive for Transfemoral Tricuspid Valve in Tricuspid Regurgitation Patients

November 8, 2021 — Results from a clinical trial of the Edwards Lifesciences Evoque transcatheter tricuspid valve ...

November 08, 2021

American Society of Nuclear Cardiology (ASNC) President Randy Thompson, M.D., getting his COVID-19 vaccine when the vaccines first became available last December. Nearly a year later, some healthcare workers are still holding out and refuse to get the vaccine, which prompted CMS (Medicare) to now require COVID vaccinations for all healthcare workers at facilities that accept Medicare and Medicaid patients.

Feature | Coronavirus (COVID-19) | By Dave Fornell, DAIC Editor

CMS Now Requires COVID-19 Vaccinations for Healthcare Workers by January 4

November 4, 2021 — The Centers for Medicare and Medicaid Services (CMS) today issued an emergency regulation now ...

November 04, 2021

Figures from an initial study on the Cardionomic CPNS technology in a poster presentation at the Heart Rhythm Society (HRS) 2021 meeting.[1] Starting at top left, an angiographic view of the atrial transseptal access for a left ventricular septal ablation. Procedural intra-cardiac echo (ICE) showing ablation catheter positioning. A 3D electro-anatomic map of the LV septum. The final graphs show baseline and post-procedure LVOT pressure readings demonstrating a decreased gradient.

News | Heart Failure

First U.S. Patient Enrolled in Cardiac Pulmonary Nerve Stimulation Pilot Study to Treat Heart Failure

November 2, 2021 — Cardionomic Inc. announce initial U.S. enrollment in its global Cardiac Pulmonary Nerve Stimulation ...

November 02, 2021

Cardiosave Hybrid Intra-Aortic Balloon Pump (IABP) left, and the Cardiosave Rescue Intra-Aortic Balloon Pump. Both systems have a recall because of reports that the battery can fail.

News | Intra-Aortic Balloon Pumps (IABP)

Cardiosave Intra-Aortic Balloon Pumps Recalled Due to Battery Failure

November 2, 2021 — Datascope/Getinge/Maquet is recalling its Cardiosave Hybrid/Rescue Intra-Aortic Balloon Pumps (IABP) ...

November 02, 2021

The FDA cleared the world's first photon-counting computed tomography (CT) scanner, the Siemens Naeotom Alpha, in late September. This new technology will likely change the future direction of CT. Biosense Webster also announced the first cases using its Heliostar radiofrequency balloon ablation catheter were completed in September. Both were among the top stories in October.

Feature | By Dave Fornell, DAIC Editor

November 1, 2021 — Here is the list of the most popular content on the Diagnostic and Interventional Cardiology (DAIC) ...

November 01, 2021

Implicity provides a remote cardiac monitoring and research platform used by Independent Diagnostic Testing Facilities and medical centers to deliver high-quality care for patients with connected cardiac devices. On this platform, Implicity aggregates, normalizes and standardizes data from any implantable cardiac device across all manufacturers.

Feature | EP Lab | By Arnaud Rosier, M.D.

Addressing Physician Concerns About Missing CIED Patient Data

With 1.2 to 1.4 million new electrophysiology (EP) devices being prescribed to patients around the world each year ...

October 28, 2021

BioCardia's CardiAMP cell therapy uses a patient’s own (autologous) bone marrow cells delivered to the heart in a minimally invasive, catheter-based procedure to potentially stimulate the body’s natural healing response. The therapy incorporates a pre-procedural screening assay to identify those patients who are likely responders to the therapy, a first for a cardiac cell therapy.

News | Stem Cell Therapies

BioCardia Announces First Patient Treated in CardiAMP Cell Therapy Trial for Chronic Myocardial Ischemia

October 28, 2021 – The first patient has been treated in a new trial using stem cell therapy to treat chronic myocardial ...

October 28, 2021